Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Female Breast Cancer Subtypes. - Cancer Stat Facts [Internet]. SEER. [cited 2024 Nov 7]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:331–57.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im S-A, Gelmon KA, et al. Overall survival with Palbociclib plus letrozole in advanced breast Cancer. JCO. 2024;42:994–1000.

Article  CAS  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, Rugo HS, Im S-A, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall survival with Palbociclib and fulvestrant in women with HR+/HER2- ABC: updated exploratory analyses of PALOMA-3, a Double-blind, phase III randomized study. Clin Cancer Res. 2022;28:3433–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line therapy for HR-Positive, advanced breast Cancer. N Engl J Med. 2016;375:1738–48.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541–7.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast Cancer. N Engl J Med. 2022;386:942–50.

Article  CAS  PubMed  Google Scholar 

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. Abemaciclib in combination with fulvestrant in women with HR+/HER2– Advanced breast Cancer who had progressed while receiving endocrine therapy. JCO. 2017;35:2875–84.

Article  CAS  Google Scholar 

Llombart-Cussac A, Sledge G, Toi M, Neven P, Sohn JH, Inoue K, et al. Overall survival analysis of monarch 2: A phase 3 trial of abemaciclib plus fulvestrant in patients with hormone Receptor-Positive, HER2-Negative advanced breast Cancer. Cancer Res. 2023;83:PD13–11.

Article  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast Cancer. J Clin Oncol. 2017;35:3638–46.

Article  CAS  PubMed  Google Scholar 

Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.

Article  PubMed  PubMed Central  Google Scholar 

Goetz M, Toi M, Huober J, Sohn JH, Trédan O, Park I et al. Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer. Cancer Research. 2024;84:GS01-12-GS01-12.

George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic differences of CDK4/6 inhibitors in breast Cancer. Front Oncol. 2021;11:693104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Prado M del, Lallena MJ et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational New Drugs. 2014;32:825.

Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin cancer Research: Official J Am Association Cancer Res. 2017;23:3251.

Article  CAS  Google Scholar 

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–38.

Article  CAS  PubMed  Google Scholar 

Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast Cancer with Palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2020;81:317.

Article  PubMed  PubMed Central  Google Scholar 

Mittal A, Valiente CM, Tamimi F, Schlam I, Sammons S, Tolaney SM, et al. Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast Cancer. Cancers. 2023;15:2015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2– metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10:104103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-Kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2016;2:1565–73.

Article  PubMed  Google Scholar 

Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

Article  Google Scholar 

O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast Cancer resistance to Palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8:1390–403.

Article  PubMed  PubMed Central  Google Scholar 

Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discov. 2020;10:1174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30:x3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. Cancer Cell. 2018;34:893.

Article  PubMed  PubMed Central  Google Scholar 

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive breast Cancer. Cancer Res. 2016;76:2301–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of resistance to CDK4/6 Blockade in advanced hormone Receptor–positive, HER2-negative breast Cancer and emerging therapeutic opportunities. Clin Cancer Res. 2022;28:821–30.

Article  CAS  PubMed  Google Scholar 

O’Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, André F, et al. Circulating tumor DNA markers for early progression on fulvestrant with or without Palbociclib in ER + Advanced breast Cancer. JNCI: J Natl Cancer Inst. 2021;113:309–17.

Article  PubMed  Google Scholar